Point72 Asset Management
ZBIO

Point72 Asset Management’s Zenas BioPharma ZBIO Stock Holding History

Point72 Asset Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$410K Buy
+16,136
New +$321K ﹤0.01% 3263
2026
Q1 		– Sell
-368,400
Closed -$9.21M – 4659
2025
Q4 		$9.21M Buy
+368,400
New +$12.1M 0.01% 1410
2024
Q4 		– Sell
-57,600
Closed -$975K – 2545
2024
Q3 		$975K Buy
+57,600
New +$1.04M ﹤0.01% 1426

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Point72 Asset Management's ZBIO Position: Q2 2026 in Review

Point72 Asset Management opened a new position in Zenas BioPharma (ZBIO) in Q2 2026: 16,136 shares worth $410K. The stake represents ﹤0.01% of the portfolio and ranks #3263 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in ZBIO as recently as Q4 2025.

Point72 Asset Management first reported a position in ZBIO in Q3 2024 and has held it in 3 quarters since. The position peaked at $9.21M in Q4 2025. 145 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Point72 Asset Management held 16,136 shares of Zenas BioPharma worth $410K as of Q2 2026.
  • Zenas BioPharma was a new Point72 Asset Management position in Q2 2026.
  • Zenas BioPharma made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #3263 holding.
  • Point72 Asset Management first reported a position in Zenas BioPharma in Q3 2024 and has held it in 3 quarters since.
  • Point72 Asset Management's Zenas BioPharma position peaked at $9.21M in Q4 2025.
  • 145 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.